Design and biological activity of (S)-4-(5-([1-(3-chlorobenzyl)-2-oxopyrrolidin-3-ylamino]methyl)imidazol-1-ylmethyl)benzonitrile, a 3-aminopyrrolidinone farnesyltransferase inhibitor with excellent cell potency |
| |
| Authors: | Bell I M Gallicchio S N Abrams M Beshore D C Buser C A Culberson J C Davide J Ellis-Hutchings M Fernandes C Gibbs J B Graham S L Hartman G D Heimbrook D C Homnick C F Huff J R Kassahun K Koblan K S Kohl N E Lobell R B Lynch J J Miller P A Omer C A Rodrigues A D Walsh E S Williams T M |
| |
| Affiliation: | Department of Medicinal Chemistry, Merck Research Laboratories, West Point, Pennsylvania 19486, USA. ian_bell@merck.com |
| |
| Abstract: | The synthesis, structure-activity relationships, and biological properties of a novel series of imidazole-containing inhibitors of farnesyltransferase are described. Starting from a 3-aminopyrrolidinone core, a systematic series of modifications provided 5h, a non-thiol, non-peptide farnesyltransferase inhibitor with excellent bioavailability in dogs. Compound 5h was found to have an unusually favorable ratio of cell potency to intrinsic potency, compared with other known FTIs. It exhibited excellent potency against a range of tumor cell lines in vitro and showed full efficacy in the K-rasB transgenic mouse model. |
| |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ |
|
